-
1
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
-
(2010)
Int J Cancer
, vol.127
, pp. 2893-2917
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
-
2
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
4
-
-
85081817391
-
-
http://www.nccn.org/default.aspx
-
-
-
-
5
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
DOI 10.1158/0008-5472.CAN-04-1443
-
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109 (Pubitemid 39331023)
-
(2004)
Cancer Research
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
Chen, C.7
Zhang, X.8
Vincent, P.9
McHugh, M.10
Cao, Y.11
Shujath, J.12
Gawlak, S.13
Eveleigh, D.14
Rowley, B.15
Liu, L.16
Adnane, L.17
Lynch, M.18
Auclair, D.19
Taylor, I.20
Gedrich, R.21
Voznesensky, A.22
Riedl, B.23
Post, L.E.24
Bollag, G.25
Trail, P.A.26
more..
-
6
-
-
79954499886
-
Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
-
Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55
-
(2011)
Int J Cancer
, vol.129
, pp. 245-255
-
-
Wilhelm, S.M.1
Dumas, J.2
Adnane, L.3
-
8
-
-
85081818459
-
-
Available from: http://www.fda.gov/
-
-
-
-
9
-
-
0005887162
-
The role of Raf kinases in malignant transformation
-
Kolch W, Kotwaliwale A, Vass K, et al. The role of Raf kinases in malignant transformation. Expert Rev Mol Med 2002;4:1-18
-
(2002)
Expert Rev Mol Med
, vol.4
, pp. 1-18
-
-
Kolch, W.1
Kotwaliwale, A.2
Vass, K.3
-
10
-
-
72449176846
-
Molecular origins of cancer: Molecular basis of colorectal cancer
-
Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60
-
(2009)
N Engl J Med
, vol.361
, pp. 2449-2460
-
-
Markowitz, S.D.1
Bertagnolli, M.M.2
-
11
-
-
0042941629
-
BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas
-
Chan TL, Zhao W, Leung SY, et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 2003;63:4878-81 (Pubitemid 37022620)
-
(2003)
Cancer Research
, vol.63
, Issue.16
, pp. 4878-4881
-
-
Chan, T.L.1
Zhao, W.2
Leung, S.Y.3
Yuen, S.T.4
-
12
-
-
80051789181
-
An update on the biology of RAS/RAF mutations in colorectal cancer
-
Nandan MO, Yang VW. An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer. Curr Colorectal Cancer Rep 2011;7:113-20
-
(2011)
Curr Colorectal Cancer Rep
, vol.7
, pp. 113-120
-
-
Nandan, M.O.1
Yang, V.W.2
-
13
-
-
0028104204
-
The ins and outs of Raf kinases
-
DOI 10.1016/0968-0004(94)90133-3
-
Daum G, Eisenmann-Tappe I, Fries HW, et al. The ins and outs of Raf kinases. Trends Biochem Sci 1994;19:474-80 (Pubitemid 24342760)
-
(1994)
Trends in Biochemical Sciences
, vol.19
, Issue.11
, pp. 474-480
-
-
Daum, G.1
Eisenmann-Tappe, I.2
Fries, H.-W.3
Troppmair, J.4
Rapp, U.R.5
-
15
-
-
0029080247
-
Constitutive activation of mitogenactivated protein (MAP) kinases in human renal cell carcinoma
-
Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogenactivated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-7
-
(1995)
Cancer Res
, vol.55
, pp. 4182-4187
-
-
Oka, H.1
Chatani, Y.2
Hoshino, R.3
-
16
-
-
2442637885
-
Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma
-
DOI 10.1016/j.hepres.2004.02.009, PII S1386634604000415
-
Hwang YH, Choi JY, Kim S, et al. Over-expression of c-raf-1 protooncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 2004;29:113-21 (Pubitemid 38667508)
-
(2004)
Hepatology Research
, vol.29
, Issue.2
, pp. 113-121
-
-
Hwang, Y.H.1
Choi, J.Y.2
Kim, S.3
Chung, E.S.4
Kim, T.5
Koh, S.S.6
Lee, B.7
Bae, S.H.8
Kim, J.9
Park, Y.M.10
-
17
-
-
0035977185
-
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer
-
DOI 10.1054/bjoc.2001.2139
-
McPhillips F, Mullen P, Monia BP, et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 2001;85:1753-8 (Pubitemid 34081523)
-
(2001)
British Journal of Cancer
, vol.85
, Issue.11
, pp. 1753-1758
-
-
McPhillips, F.1
Mullen, P.2
Monia, B.P.3
Ritchie, A.A.4
Dorr, F.A.5
Smyth, J.F.6
Langdon, S.P.7
-
18
-
-
19544370522
-
Raf-1 expression may influence progression to androgen insensitive prostate cancer
-
DOI 10.1002/pros.20211
-
Mukherjee R, Bartlett JM, Krishna NS, et al. Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate 2005;64:101-7 (Pubitemid 40734744)
-
(2005)
Prostate
, vol.64
, Issue.1
, pp. 101-107
-
-
Mukherjee, R.1
Bartlett, J.M.S.2
Krishna, N.S.3
Underwood, M.A.4
Edwards, J.5
-
19
-
-
33749238553
-
Discovery and development of sorafenib: A multikinase inhibitor for treating cancer
-
DOI 10.1038/nrd2130, PII NRD2130
-
Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44 (Pubitemid 44480537)
-
(2006)
Nature Reviews Drug Discovery
, vol.5
, Issue.10
, pp. 835-844
-
-
Wilhelm, S.1
Carter, C.2
Lynch, M.3
Lowinger, T.4
Dumas, J.5
Smith, R.A.6
Schwartz, B.7
Simantov, R.8
Kelley, S.9
-
20
-
-
78449292368
-
BRAF inactivation drives aneuploidy by deregulating CRAF
-
Kamata T, Hussain J, Giblett S, et al. BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res 2010;70:8475-86
-
(2010)
Cancer Res
, vol.70
, pp. 8475-8486
-
-
Kamata, T.1
Hussain, J.2
Giblett, S.3
-
21
-
-
74849109743
-
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
-
Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21
-
(2010)
Cell
, vol.140
, pp. 209-221
-
-
Heidorn, S.J.1
Milagre, C.2
Whittaker, S.3
-
22
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF
-
Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wildtype BRAF. Nature 2010;464:427-30
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
Zhang, C.2
Bollag, G.3
-
23
-
-
29144462587
-
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
-
DOI 10.1016/j.molcel.2005.10.022, PII S109727650501717X
-
Garnett MJ, Rana S, Paterson H, et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005;20:963-9 (Pubitemid 41814884)
-
(2005)
Molecular Cell
, vol.20
, Issue.6
, pp. 963-969
-
-
Garnett, M.J.1
Rana, S.2
Paterson, H.3
Barford, D.4
Marais, R.5
-
24
-
-
0035935203
-
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: Identification of a second generation lead by a combinatorial chemistry approach
-
DOI 10.1016/S0960-894X(01)00571-6, PII S0960894X01005716
-
Smith RA, Barbosa J, Blum CL, et al. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg Med Chem Lett 2001;11:2775-8 (Pubitemid 32925314)
-
(2001)
Bioorganic and Medicinal Chemistry Letters
, vol.11
, Issue.20
, pp. 2775-2778
-
-
Smith, R.A.1
Barbosa, J.2
Blum, C.L.3
Bobko, M.A.4
Caringal, Y.V.5
Dally, R.6
Johnson, J.S.7
Katz, M.E.8
Kennure, N.9
Kingery-Wood, J.10
Lee, W.11
Lowinger, T.B.12
Lyons, J.13
Marsh, V.14
Rogers, D.H.15
Swartz, S.16
Walling, T.17
Wild, H.18
-
25
-
-
0036401042
-
Design and discovery of small molecules targeting Raf-1 kinase
-
DOI 10.2174/1381612023393125
-
Lowinger TB, Riedl B, Dumas J, et al. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002;8:2269-78 (Pubitemid 35189900)
-
(2002)
Current Pharmaceutical Design
, vol.8
, Issue.25
, pp. 2269-2278
-
-
Lowinger, T.B.1
Riedl, B.2
Dumas, J.3
Smith, R.A.4
-
26
-
-
1642534327
-
Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent
-
DOI 10.1016/j.bmcl.2003.11.041
-
Khire UR, Bankston D, Barbosa J, et al. Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent. Bioorg Med Chem Lett 2004;14:783-6 (Pubitemid 38114872)
-
(2004)
Bioorganic and Medicinal Chemistry Letters
, vol.14
, Issue.3
, pp. 783-786
-
-
Khire, U.R.1
Bankston, D.2
Barbosa, J.3
Brittelli, D.R.4
Caringal, Y.5
Carlson, R.6
Dumas, J.7
Gane, T.8
Heald, S.L.9
Hibner, B.10
Johnson, J.S.11
Katz, M.E.12
Kennure, N.13
Kingery-Wood, J.14
Lee, W.15
Liu, X.-G.16
Lowinger, T.B.17
McAlexander, I.18
Monahan, M.-K.19
Natero, R.20
Renick, J.21
Riedl, B.22
Rong, H.23
Sibley, R.N.24
Smith, R.A.25
Wolanin, D.26
more..
-
27
-
-
0344177511
-
A scintillation proximity assay for the raf/MEK/ERK kinase cascade: High-throughput screening and identification of selective enzyme inhibitors
-
DOI 10.1006/abio.1998.3030
-
McDonald OB, Chen WJ, Ellis B, et al. A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: highthroughput screening and identification of selective enzyme inhibitors. Anal Biochem 1999;268:318-29 (Pubitemid 29147147)
-
(1999)
Analytical Biochemistry
, vol.268
, Issue.2
, pp. 318-329
-
-
McDonald, O.B.1
Chen, W.J.2
Ellis, B.3
Hoffman, C.4
Overton, L.5
Rink, M.6
Smith, A.7
Marshall, C.J.8
Wood, E.R.9
-
28
-
-
33744513575
-
®), a Dual-Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature
-
DOI 10.1016/S0076-6879(05)07047-3, PII S0076687905070473, Regulators and Effectors of Small GTPases: Ras Family
-
Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612 (Pubitemid 43815979)
-
(2005)
Methods in Enzymology
, vol.407
, pp. 597-612
-
-
Adnane, L.1
Trail, P.A.2
Taylor, I.3
Wilhelm, S.M.4
-
29
-
-
33846212284
-
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
-
DOI 10.1158/0008-5472.CAN-06-1377
-
Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8 (Pubitemid 46094197)
-
(2006)
Cancer Research
, vol.66
, Issue.24
, pp. 11851-11858
-
-
Liu, L.1
Cao, Y.2
Chen, C.3
Zhang, X.4
McNabola, A.5
Wilkie, D.6
Wilhelm, S.7
Lynch, M.8
Carter, C.9
-
30
-
-
33847118123
-
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
-
DOI 10.1007/s00280-006-0393-4
-
Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74 (Pubitemid 46295136)
-
(2007)
Cancer Chemotherapy and Pharmacology
, vol.59
, Issue.5
, pp. 561-574
-
-
Chang, Y.S.1
Adnane, J.2
Trail, P.A.3
Levy, J.4
Henderson, A.5
Xue, D.6
Bortolon, E.7
Ichetovkin, M.8
Chen, C.9
McNabola, A.10
Wilkie, D.11
Carter, C.A.12
Taylor, I.C.A.13
Lynch, M.14
Wilhelm, S.15
-
31
-
-
55749088393
-
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
-
Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 3129-3140
-
-
Wilhelm, S.M.1
Adnane, L.2
Newell, P.3
-
32
-
-
12144289677
-
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
-
DOI 10.1016/S0092-8674(04)00215-6, PII S0092867404002156
-
Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67 (Pubitemid 38410730)
-
(2004)
Cell
, vol.116
, Issue.6
, pp. 855-867
-
-
Wan, P.T.C.1
Garnett, M.J.2
Roe, S.M.3
Lee, S.4
Niculescu-Duvaz, D.5
Good, V.M.6
Project, C.G.7
Jones, C.M.8
Marshall, C.J.9
Springer, C.J.10
Barford, D.11
Marais, R.12
-
33
-
-
33744984843
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
-
DOI 10.1200/JCO.2005.03.6723
-
Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12 (Pubitemid 46630627)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.16
, pp. 2505-2512
-
-
Ratain, M.J.1
Eisen, T.2
Stadler, W.M.3
Flaherty, K.T.4
Kaye, S.B.5
Rosner, G.L.6
Gore, M.7
Desai, A.A.8
Patnaik, A.9
Xiong, H.Q.10
Rowinsky, E.11
Abbruzzese, J.L.12
Xia, C.13
Simantov, R.14
Schwartz, B.15
O'Dwyer, P.J.16
-
34
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
DOI 10.1038/nature00766
-
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54 (Pubitemid 34716871)
-
(2002)
Nature
, vol.417
, Issue.6892
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
Teague, J.7
Woffendin, H.8
Garnett, M.J.9
Bottomley, W.10
Davis, N.11
Dicks, E.12
Ewing, R.13
Floyd, Y.14
Gray, K.15
Hall, S.16
Hawes, R.17
Hughes, J.18
Kosmidou, V.19
Menzies, A.20
Mould, C.21
Parker, A.22
Stevens, C.23
Watt, S.24
Hooper, S.25
Wilson, R.26
Jayatilake, H.27
Gusterson, B.A.28
Cooper, C.29
Shipley, J.30
Hargrave, D.31
Pritchard-Jones, K.32
Maitland, N.33
Chenevix-Trench, G.34
Riggins, G.J.35
Bigner, D.D.36
Palmleri, G.37
Cossu, A.38
Flanagan, A.39
Nicholson, A.40
Ho, J.W.C.41
Leung, S.Y.42
Yuen, S.T.43
Weber, B.L.44
Seigler, H.F.45
Darrow, T.L.46
Paterson, H.47
Marais, R.48
Marshall, C.J.49
Wooster, R.50
Stratton, M.R.51
Futreal, P.A.52
more..
-
35
-
-
84941140761
-
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
-
[Epub ahead of print]
-
Schmieder R, Hoffmann J, Becker M, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer 2013. [Epub ahead of print]
-
Int J Cancer 2013
-
-
Schmieder, R.1
Hoffmann, J.2
Becker, M.3
-
36
-
-
84880075006
-
Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model
-
Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013;12:1322-31
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 1322-1331
-
-
Abou-Elkacem, L.1
Arns, S.2
Brix, G.3
-
37
-
-
84884737517
-
Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation
-
Cyran CC, Kazmierczak PM, Hirner H, et al. Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS One 2013;8:e76009
-
(2013)
PLoS One
, vol.8
-
-
Cyran, C.C.1
Kazmierczak, P.M.2
Hirner, H.3
-
38
-
-
84860531989
-
A phase i dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors
-
Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012;18:2658-67
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2658-2667
-
-
Mross, K.1
Frost, A.2
Steinbild, S.3
-
39
-
-
84861459479
-
Regorafenib (BAY 73-4506) in advanced colorectal cancer: A phase i study
-
Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012;106:1722-7
-
(2012)
Br J Cancer
, vol.106
, pp. 1722-1727
-
-
Strumberg, D.1
Scheulen, M.E.2
Schultheis, B.3
-
40
-
-
84899121465
-
Regorafenib in Japanese patients with solid tumors: Phase i study of safety, efficacy, and pharmacokinetics
-
Sunakawa Y, Furuse J, Okusaka T, et al. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs 2014;32:104-12
-
(2014)
Invest New Drugs
, vol.32
, pp. 104-112
-
-
Sunakawa, Y.1
Furuse, J.2
Okusaka, T.3
-
41
-
-
84872921660
-
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebocontrolled, phase 3 trial
-
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 2013;381:303-12
-
(2013)
Lancet
, vol.381
, pp. 303-312
-
-
Grothey, A.1
Van Cutsem, E.2
Sobrero, A.3
-
42
-
-
0027461840
-
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
-
Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-5 (Pubitemid 23080053)
-
(1993)
British Medical Journal
, vol.306
, Issue.6880
, pp. 752-755
-
-
Scheithauer, W.1
Rosen, H.2
Kornek, G.-V.3
Sebesta, C.4
Depisch, D.5
-
43
-
-
34548144472
-
Palliative chemotherapy for advanced or metastatic colorectal cancer
-
Colorectal meta-analysis collaboration
-
Colorectal meta-analysis collaboration. Palliative chemotherapy for advanced or metastatic colorectal cancer. colorectal meta-analysis collaboration. Cochrane Database Syst Rev 2000(2):CD001545
-
(2000)
Colorectal Meta-analysis Collaboration. Cochrane Database Syst Rev
, vol.2
-
-
-
44
-
-
0034727063
-
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
-
Irinotecan Study Group
-
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14
-
(2000)
N Engl J Med
, vol.343
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
-
45
-
-
0033874892
-
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
-
de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47 (Pubitemid 30644117)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.16
, pp. 2938-2947
-
-
De Gramont, A.1
Figer, A.2
Seymour, M.3
Homerin, M.4
Hmissi, A.5
Cassidy, J.6
Boni, C.7
Cortes-Funes, H.8
Cervantes, A.9
Freyer, G.10
Papamichael, D.11
Le Bail, N.12
Louvet, C.13
Hendler, D.14
De Braud, F.15
Wilson, C.16
Morvan, F.17
Bonetti, A.18
-
46
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
47
-
-
2142703727
-
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
-
DOI 10.1200/JCO.2004.11.037
-
Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14 (Pubitemid 41079833)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.7
, pp. 1209-1214
-
-
Grothey, A.1
Sargent, D.2
Goldberg, R.M.3
Schmoll, H.-J.4
-
48
-
-
84899100865
-
Future of targeted agents in metastatic colorectal cancer
-
doi:10.2217/crc.12.52
-
Burotto M, Hartley ML, Marshall JL, et al. Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer 2012;1, doi:10.2217/crc.12.52
-
(2012)
Colorectal Cancer
, vol.1
-
-
Burotto, M.1
Hartley, M.L.2
Marshall, J.L.3
-
49
-
-
84878442416
-
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: Results of a multicenter, phase Ib study
-
Schultheis B, Folprecht G, Kuhlmann J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol 2013;2:1560-7
-
(2013)
Ann Oncol
, vol.2
, pp. 1560-1567
-
-
Schultheis, B.1
Folprecht, G.2
Kuhlmann, J.3
-
50
-
-
84863283404
-
Molecular targeted therapies for cancer: Sorafenib mono-therapy and its combination with other therapies (review)
-
Ibrahim N, Yu Y, Walsh WR, et al. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep 2012;27:1303-11
-
(2012)
Oncol Rep
, vol.27
, pp. 1303-1311
-
-
Ibrahim, N.1
Yu, Y.2
Walsh, W.R.3
-
51
-
-
79959433553
-
Transformation of in vitro tools for kinase profiling: Keeping an eye over the off-target liabilities
-
Bi K, Lebakken CS, Vogel KW. Transformation of in vitro tools for kinase profiling: keeping an eye over the off-target liabilities. Expert Opin Drug Discov 2011;6:701-12
-
(2011)
Expert Opin Drug Discov
, vol.6
, pp. 701-712
-
-
Bi, K.1
Lebakken, C.S.2
Vogel, K.W.3
-
52
-
-
33745298429
-
Rational design of inhibitors that bind to inactive kinase conformations
-
DOI 10.1038/nchembio799, PII N799
-
Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-64 (Pubitemid 43936934)
-
(2006)
Nature Chemical Biology
, vol.2
, Issue.7
, pp. 358-364
-
-
Liu, Y.1
Gray, N.S.2
-
53
-
-
57749188299
-
Targeting cancer with small molecule kinase inhibitors
-
Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 28-39
-
-
Zhang, J.1
Yang, P.L.2
Gray, N.S.3
-
54
-
-
84890484498
-
Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer
-
Zámečníkova A. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. Expert Opin Drug Discov 2014;9:77-92
-
(2014)
Expert Opin Drug Discov
, vol.9
, pp. 77-92
-
-
Zámečníkova, A.1
-
55
-
-
84891671103
-
Regorafenib: A novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors
-
Crona DJ, Keisler MD, Walko CM. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. Ann Pharmacother 2013;47:1685-96
-
(2013)
Ann Pharmacother
, vol.47
, pp. 1685-1696
-
-
Crona, D.J.1
Keisler, M.D.2
Walko, C.M.3
|